Canadian MPN Group

What Canadian MPN Group does

The Canadian MPN Group is a national, donation-funded charitable organization established in 2013 and headquartered within the Division of Hematology at the Jewish General Hospital in Montreal, Canada. Its mission is to improve the care and research for patients with myeloproliferative neoplasms (PV, ET, PMF) through inter-professional collaboration. It operates as Canada's first national physician-driven MPN collaborative, with named executive members at McGill, University of Toronto, UBC, McMaster, and University of Calgary and a treatment-center footprint across British Columbia, Alberta, Saskatchewan, Ontario, Quebec, and Nova Scotia. End users are two distinct segments: MPN patients and caregivers seeking information, support, and clinical-trial access, and hematologists, medical oncologists, and researchers using the Group's tools, Tumor Board, and guidelines in daily practice.

The Group's product portfolio spans digital clinical/research tools, content, and clinical programs. Core technology includes Pallas (a GPT-based AI research assistant for MPN/oncology/hematology queries), the MPN eSIMPLE clinical decision-support app for Canadian physicians (supported by Novartis Oncology), the MPN Updates digital-publication app (sponsored by Incyte Corp.), and a Research Data Platform aggregating NCBI resources (TCGA, COSMIC, BLAST, ClinVar, dbSNP, dbVar, Genome Data Viewer, NCBI Gene Resources, GTR, Batch Entrez). Clinical programs include a structured Tumor Board (multidisciplinary case review using WHO/ICC classification, marrow morphology, cytogenetics, driver mutations, symptom scoring via MPN-SAF TSS 2.0, and risk-stratification tools such as DIPSS, IPSET-Thrombosis, and MYSEC-PM), the Conversations in MPN multi-stakeholder forum, and the prospective National MPN Database currently under development, alongside a Pregnancy in MPN prospective observational study.

Business model: charitable, donation-funded, services provided free of charge. Go-to-market runs through mpncanada.org, the treatment-center network, an international collaborative network (mutually endorsed linkages with ASH, EHA, ISH, ISLH, ESMO, ASCO, and the Canadian Hematology Society), and partnerships with MPN Research Foundation, Leukemia & Lymphoma Society, and MPD Voice. Revenue is not disclosed; the principal named funders are Ed Pascal (founding supporter), Tony Comper (former BMO CEO; website funding and Elizabeth and Tony Comper MPN Program at Princess Margaret Cancer Centre), and Novartis Oncology. There is no headcount, employee count, or funded capital structure disclosed; ownership is governed by the executive hematologist team led by Dr. Shireen Sirhan (President).

Name

Canadian MPN Group

Legal name

Canadian MPN Group

Website

https://mpncanada.org

Company type

Private

Founded year

2013

Operating status

Operating

Short description

The Canadian MPN Group is a donation-funded Canadian charity that coordinates hematologists, researchers, and patients to advance diagnosis, treatment, research, and education for myeloproliferative neoplasms. It delivers the Pallas AI research assistant, MPN eSIMPLE clinical decision-support app, and a national treatment-center network.

Ownership category

akta.pro rank

Product category

Hematology Clinical Decision Support and Patient Education

NAICS

Professional Organizations (81392)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Myeloproliferative neoplasm research
• Clinical decision support
• Hematology physician network
• MPN patient education
• AI medical research tools

Headquarters

HQ city

Montreal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels3 records

Marketing channels5 records

Core offering

Canadian MPN Group is a Canadian charitable nonprofit organization focused on myeloproliferative neoplasms (MPNs). It operates a national physician network, runs a tumor board for clinical decision support, and develops digital tools including the MPN eSIMPLE clinical app and the Pallas AI research assistant. The organization also delivers patient-facing educational resources such as its "Living with MPNs" program.

Product overview

The Canadian MPN Group operates as a national charitable organization and collaborative network rather than a single product company. Its portfolio consists of digital tools and programs: Pallas (a GPT-based AI research assistant), the Collaborative Network Search Tool (a directory for connecting with global healthcare communities), the MPN Research Data and Tools Platform (accessing genomic databases such as TCGA, COSMIC, BLAST), the MPN eSIMPLE App (a physician clinical decision-support tool), and the MPN Updates App (a patient/caregiver digital publication). These are supplemented by clinical programs — the Tumor Board (multidisciplinary case review), Conversations in MPN (multi-stakeholder forum), and the National MPN Database (planned national registry) — and a Pregnancy in MPN prospective observational study. All offerings are oriented toward improving MPN patient care, research, and physician education across Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• MPN Tumor Board
• MPN eSIMPLE App Digital clinical tool designed to assist healthcare professionals in the assessment and management of myeloproliferative neoplasms.
• Pallas AI Artificial-intelligence research assistant developed by the organization to support MPN-related clinical reasoning and research activities.
• Living with MPNs (Patient Education Program) Educational resource hub for MPN patients and caregivers providing information about diagnosis, treatment options, and day-to-day management of myeloproliferative neoplasms.

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Canadian Hematology Society (CHS-SCH)coreStrategic or Co-development PartnerProfessional association founded in 1971 whose membership includes most hematologists in Canada. The CHS is endorsed by the Canadian MPN Group as a key professional resource.
• American Society of Hematology (ASH)coreStrategic or Co-development PartnerWorld's largest professional society of clinicians and scientists dedicated to conquering blood diseases. ASH has led development of hematology since 1958 through research, patient care, education, training, and advocacy.
• European Hematology Association (EHA)coreStrategic or Co-development PartnerLargest Europe-based organization for hematologists, dedicated to advancing excellence in patient care, research, and education within hematology.
• International Society of Hematology (ISH)coreStrategic or Co-development PartnerOldest and only world hematology organization established by national hematology societies in 1946. Dedicated to education of professionals and public in all areas of hematology.
• Princess Margaret Cancer CentrecoreStrategic or Co-development PartnerWorld-class MPN treatment program funded by Tony Comper's generous donation. Houses the Elizabeth and Tony Comper MPN Program and serves as a key research and treatment center.
• Jewish General Hospital (McGill)coreStrategic or Co-development PartnerLocation of the myeloproliferative neoplasms clinic established by Dr. Shireen Sirhan and Dr. Jaroslav Prchal. Serves as headquarters for the Canadian MPN Group.
• MPN Research FoundationminorStrategic or Co-development PartnerNon-profit organization whose mission is to promote, fund and support the most innovative and effective research into the causes, treatments, and potentially the cure for PV, ET and myelofibrosis.
• Leukemia & Lymphoma Society (LLS)minorStrategic or Co-development PartnerWorld's largest non-profit health agency dedicated to helping patients with blood cancer and their families. Provides free information and support services.
• MPD VoiceminorStrategic or Co-development PartnerUK-based patient organization established by MPN patients with active online community and up-to-date information on ET, PV and myelofibrosis.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• MPN Research Foundation: US-based nonprofit whose mission is to fund and support research into PV, ET, and myelofibrosis — the same three MPN subtypes addressed by Canadian MPN Group. Directly comparable as a disease-specific MPN research and patient-advocacy nonprofit operating in the same patient population.
• MPD Voice: UK-based patient organization established by MPN patients providing information and community support for ET, PV, and myelofibrosis. Direct disease-specific peer, regionally distinct from Canadian MPN Group but serving the identical patient population and mission.

Broad incumbents

• National Comprehensive Cancer Network (NCCN): US-based alliance of leading academic cancer centers issuing widely used oncology clinical practice guidelines, including for MPNs. Comparable as a guideline-issuing body whose MPN guidance shapes Canadian physician practice alongside Canadian MPN Group's outputs.
• American Society of Hematology (ASH): Largest professional society of hematologists worldwide, focused on blood disease research, education, and advocacy. A core strategic partner of Canadian MPN Group; comparable as a hematology-wide body that encompasses MPN as a subspecialty.
• European Hematology Association (EHA): Largest Europe-based organization for hematologists advancing patient care, research, and education. Direct strategic partner of Canadian MPN Group; operates on a broader hematology remit while intersecting on MPN content and guidelines.
• International Society of Hematology (ISH): World's oldest hematology organization founded in 1946, dedicated to education across all hematology areas. Listed as a partner of Canadian MPN Group and overlaps on MPN-focused education and congresses.
• Leukemia & Lymphoma Society (LLS): World's largest nonprofit dedicated to blood cancer patients, providing information, support, and research funding. Listed as a partner of Canadian MPN Group; a broader incumbent that covers MPNs within a much wider blood-cancer portfolio.

Emerging players

• MPN Hub: Online medical education platform providing hematology-oncology professionals with up-to-date information on MPNs and other blood cancers. An emerging content/digital peer overlapping with Canadian MPN Group's clinical education and research-support offerings.

Regional players

• Princess Margaret Cancer Centre: Toronto-based world-class MPN treatment program that houses the Elizabeth and Tony Comper MPN Program and is a strategic partner and treatment-center node for Canadian MPN Group. Comparable as a leading MPN clinical-research site rather than a peer nonprofit.
• Canadian Hematology Society (CHS-SCH): Canadian professional hematology association founded in 1971 whose membership includes most Canadian hematologists. Endorsed by Canadian MPN Group as a key professional resource; comparable as the national hematology professional body.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canadian MPN Group